ClinicalTrials.gg
RecruitingNCT06505577Updated Nov 6, 2026

Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study

An observational study in Mastectomy and Breast Neoplasm Malignant Primary, sponsored by Incheon St.Mary's Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Incheon St.Mary's Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.

Planned enrollment
44th of 109
600 · median 444
Started
2024
with 36 others
Observational
110 of 618
30 open now
Primary completion
2027-12
later than 143 of 229 live
Registered
542nd of 618
by date

Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 44th largest by planned enrollment of the 109 observational ones that give a count, is one of 37 that started in 2024, is one of 110 observational ones, reaches primary completion later than 143 of the 229 other live ones, and was the 542nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

127 more — sign in →

All 132 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 618 studies in Breast Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging. Inadequate resection margins necessitate reoperation, leading to increased psychological stress, costs, and potentially compromised cosmetic outcomes and prognosis.

Accurate preoperative assessment of resection extent is crucial and involves various factors, including imaging studies, physical examinations, tumor molecular subtypes, and intraductal carcinoma components. This prospective observational study aims to identify and integrate multiple predictive factors to enhance surgical planning and minimize reoperation rates in breast cancer patients.

Read the detailed description

Breast cancer is the most prevalent malignancy among women globally, leading to surgical interventions for non-metastatic cases. While breast cancer generally has a favorable prognosis, achieving negative resection margins at initial surgery is crucial for optimal outcomes. The challenge associated with accurately predicting the extent of resection preoperatively, as failure to secure clear margins may necessitate further resection or total mastectomy, resulting in increased psychological stress, higher healthcare costs, compromised cosmetic results, and potential negative impacts on long-term prognosis and quality of life. Many factors contribute to predicting the optimal resection extent, including imaging studies, physical examination findings, tumor molecular subtypes, presence and extent of intraductal carcinoma components, etc. Despite the availability of these predictive factors, their integration and practical application in clinical decision-making remain challenging. This prospective observational study aims to address this gap by analyzing the interplay of these factors in real-world clinical settings, with the primary objective of deriving an integrated predictive model to guide surgeons in determining the optimal extent of resection preoperatively.

03

Conditions studied

  • Mastectomy
  • Breast Neoplasm Malignant Primary

Keywords

  • Breast cancer
  • Mastectomy
  • Ductal carcinoma in situ
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will be enrolled from patients at Incheon Saint Mary's Hospital, a 1000-bed tertiary academic medical center located in Incheon, South Korea.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients (≥ 19 years old) diagnosed with breast cancer (invasive and in situ).

Patients scheduled for surgical resection of the tumor Availability of both preoperative tumor size assessments and pathologic measurements post-surgery

Exclusion criteria

Exclusion Criteria:

Patients with recurrent breast cancer Inflammatory breast cancer Patients who did not undergo surgery Patients whose preoperative tumor size data is not available or deficient for analyzing

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Breast cancer surgery group

    This cohort includes all patients undergoing breast cancer surgery who are enrolled in the study.

    Other: No additional intervention

Interventions

  • OtherNo additional intervention

    All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.

06

What researchers measure

Primary outcomes

  1. Concordance rate by the intraclass correlation coefficient Factors associated with discrepancies

    To assess the concordance between preoperative tumor size assessments made by surgeons and the actual tumor size determined by pathologic analysis following surgical resection in patients with breast cancer. * Using the scale of Landis and Koch according to the intraclass correlation coefficient. * With/without MRI status. To identify and evaluate factors associated with discrepancies between preoperative assessments and pathologic measurements.

    Time frame: Within 30 days after surgery

Secondary outcomes

  1. Concordance rate by size discordance (5mm) To evaluate the concordance between preoperative tumor size assessments and pathologic measurements in the subgroup of patients with ductal carcinoma in situ (DCIS)

    To assess the concordance between preoperative tumor size assessments made by surgeons and the actual tumor size determined by pathologic analysis following surgical resection in patients with breast cancer. A difference of 5mm or more between preoperative and pathologic measurements is defined as discordance.

    Time frame: Within 30 days after surgery

  2. Concordance rate and discrepancy factor in ductal carcinoma in situ (DCIS) subgroup

    To evaluate the concordance between preoperative tumor size assessments and pathologic measurements in the subgroup of patients with ductal carcinoma in situ (DCIS).

    Time frame: Within 30 days after surgery

  3. Concordance rate and discrepancy factor in neoadjuvant systemic therapy subgroup

    To assess the concordance between preoperative tumor size assessments and pathologic measurements in the subgroup of patients who received neoadjuvant systemic therapy

    Time frame: Within 30 days after surgery

  4. Proportion of surgical method change: rates of unnecessary total mastectomy

    To determine the rate of change in surgical method (e.g., from lumpectomy to mastectomy, nipple-sparing to skin-sparing, or vice versa) based on discrepancies between preoperative tumor size assessments and pathologic measurements. This involves collecting the initial surgical method plan from the surgeon before the surgery and, after confirming the pathological size post-surgery, collecting the final surgical method deemed feasible for the patient from the surgeon.

    Time frame: Within 30 days after surgery

  5. Factors requiring MRI: factors associated with size discrepancy between MRI and mammography (with/without Breast ultrasonography)

    To determine the associated factors contributing to size discrepancies between mammography (with or without breast ultrasonography) and MRI. For analyzing the clinical factors that necessitate the use of MRI to predict the pathologic tumor size.

    Time frame: Within 30 days after surgery

  6. Rate of recurrence within 1-year after breast surgery

    The proportion of patients who develop new malignant lesions during the follow-up period within 1 year after breast surgery.

    Time frame: Within 1 year after enroll

07

Study locations

1 of 1 sites recruiting
  • Incheon St. Mary's Hospital
    Incheon, South Korea
    Recruiting
    • Young-Joon Kang, MD, PhD · Contactyjkang.md@gmail.com · 82-32-280-5179
    • Young-Joon Kang, MD, PhD · Principal investigator
    • Jae Pak Yi, MD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 40 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2026 → Dec 2027 and completion Aug 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2024
First posted
Jul 17, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Dec 31, 2027was Aug 2026
CompletionEst.
Feb 28, 2028was Aug 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 30, 2026→Dec 31, 2027
Nov 6, 2026
Study completion
Aug 30, 2027→Feb 28, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Aug 30, 2026→Dec 31, 2027
    Study completion Aug 30, 2027→Feb 28, 2028
    + 4 other changes: index terms, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06505577
Lead sponsor
Incheon St.Mary's Hospital
Collaborators
Yonsei University
Responsible party
Young-Joon Kang (Assistant Professor, Incheon St.Mary's Hospital) — Principal investigator
First posted
Jul 17, 2024
Start date
Aug 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Young-Joon Kang, Ph.D.
Contact
yjkang.md@gmail.com
82 32-280-5179

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion